Best of ASCO - 2014 Annual Meeting



Attend this session at the
2018 ASCO Annual Meeting!

Session: Melanoma/Skin Cancers

Type: Poster Session

Time: Monday June 4, 1:15 PM to 4:45 PM

Location: Hall A

Radioembolization for treatment of uveal melanoma hepatic metastasis: Results of a phase II, single institution, prospective trial.

Advanced Disease

Melanoma/Skin Cancers

2018 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #362)

J Clin Oncol 36, 2018 (suppl; abstr 9535)

Author(s): Carin F. Gonsalves, David J. Eschelman, Robert D. Adamo, P. Rani Anne, Marlana M. Orloff, Takami Sato; Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA; Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA

Abstract Disclosures


Background: The liver is the first site of metastasis in > 90% of uveal melanoma (UM) patients. Transarterial catheter directed therapies have been used to control growth of liver tumors and prolong overall survival (OS). We report results of the first prospective, phase II trial using radioembolization ([RE] Y-90 resin microspheres) for treatment of UM hepatic metastases. Methods: Between November 2011 and January 2017, RE was performed on 24 treatment naïve patients [Group A (13 men; median age 63; range, 29 -77)] and 24 patients who progressed after immunoembolization [Group B (9 men; median age 59, range, 34-77)]. Patients received unilobar or lobar treatments separated by 3-5 weeks. Patients were followed for 1 month for acute toxicity and every 3 months for delayed toxicity (CTCAE v 3.0). MR, CT and PET imaging was obtained every 3 months to evaluate for tumor response (PFS; RECIST) and extrahepatic disease. Results: Group A: Unilobar (n = 7) or bilobar (n = 17) RE was performed (median dose, 32.6 mCi; range, 17.7-56.1). One patient was removed from the trial for incomplete lobar treatment. RE response included PR (n = 7), SD (n = 13) and PD (n = 3). Median PFS was 8.1 months (range, 3.3 - 33.7). Median OS was 18.9 months (range, 6.5 -66.9) with 4 surviving patients (range, 14.0-66.9 months). One year survival was 61%. Extrahepatic disease occurred in 17 patients (median, 6.3 months; range, 3.3 – 11.9). Group B: Unilobar (n = 5) or bilobar (n = 19) RE was performed (median dose, 35.0 mCi; range, 19.2 -50.8). RE response included PR (n = 6), SD (n = 8) and PD (n = 10). One patient withdrew from the trial. Median PFS was 4.3 months (range, 2.5 -18.6). Median OS was 19.1 months (range, 4.8-68.4) with 5 surviving patients (range, 18.6 – 68.4 months). One year survival was 70%. Extrahepatic disease occurred in 15 patients (median, 5.5 months; range 0.8-9.9). No procedure-related complications occurred. Grade 3 treatment-related toxicities included transient leukopenia (n = 2), nausea/vomiting (n = 1) and pain (n = 1). Conclusions: RE is a safe and effective treatment for UM hepatic metastases and should be considered as a treatment option for patients with and without prior transarterial catheter directed therapies. Clinical trial information: NCT01473004

Other Abstracts in this Sub-Category:


1. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 108 First Author: Georgina V. Long
Category: Melanoma/Skin Cancers - Advanced Disease


2. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Meeting: 2018 ASCO Annual Meeting Abstract No: 9503 First Author: Georgina V. Long
Category: Melanoma/Skin Cancers - Advanced Disease


3. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.

Meeting: 2018 ASCO Annual Meeting Abstract No: 9504 First Author: Reinhard Dummer
Category: Melanoma/Skin Cancers - Advanced Disease